ArticleProbiotics and antimicrobial proteins2026
Unraveling Streptococcus Thermophilus NCU074001-Based Anti-Diarrheal Actions Via Integrated Immune-Gut Microbiota and Tryptophan Metabolic Pathway Identification.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Diarrhea, a common gastrointestinal disorder, is often exacerbated by conventional antibiotic treatments that disrupt gut microbiota, necessitating the exploration of Lactic acid bacteria (LAB) alternatives. This study investigates the therapeutic potential and mechanisms of Streptococcus thermophilus NCU074001 (ST) in a rat model of PEG3350-induced osmotic diarrhea. ST treatment mitigated diarrheal symptoms and improved key markers of intestinal health by acting as a key modulator of the gut ecosystem. Its efficacy was driven by balancing immune responses via elevated IL-10 and suppressed pro-inflammatory cytokines (IL-6, IL-1β, TNF-α, IFN-γ). Furthermore, ST reinforced the intestinal barrier by upregulating MUC2 expression and reshaping gut microbial ecology by suppressing certain genera (Bacteroides and Anaerofilum) while enriching others (Lactobacillus, Akkermansia, Phascolarctobacterium, and Parabacteroides). This taxonomic restoration was accompanied by a functional metabolic shift, characterized by increased production of short-chain fatty acids (acetate and butyrate) and a targeted modulation of tryptophan metabolism that enhanced the production of anti-inflammatory indole derivatives. Correlation analyses suggested potential links between ST-mediated microbiota remodeling and barrier strengthening and immunomodulation. Collectively, these results indicate that ST functions as a promising probiotic integrating immunomodulation, microbiota restoration, and metabolic reprogramming to alleviate diarrhea, and thus presents a promising therapeutic alternative to conventional antibiotics.
Indexed as
Identifiers
41499039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.